获得性痣皮肤镜亚型的BRAF与NRAS突变 prevalence 揭示MAPK通路组成性激活
研究对27名参与者共40个获得性痣(球状、网状、球周缘亚型)采用ddPCR检测BRAF与NRAS突变。结论支持MAPK通路在良性黑素细胞增生中的作用。
要点
- 所有检测的获得性痣均携带BRAF或NRAS突变。
- 球状和球周缘痣以BRAF突变为主,网状痣BRAF与NRAS突变并存。
- BRAF/NRAS突变不足以独立驱动黑色素瘤发生。
核心结论
- 所有评估的获得性痣均存在BRAF或NRAS突变,提示MAPK通路激活在良性黑素细胞增生中普遍存在。
主要发现
- BRAF V600E或V600K突变在85%(34/40)的痣中检出。
- 所有BRAF野生型痣(15%,6/40)均携带NRAS密码子12/13或61突变。
- 球状痣BRAF突变率为92%(12/13),球周缘痣为100%(12/12)。
临床怎么用
- 皮肤镜亚型可提示获得性痣的突变谱,但BRAF或NRAS突变不能单独作为黑色素瘤诊断标志。
局限性
- 样本量较小(40个痣),仅纳入三种皮肤镜亚型,未涉及其他亚型或前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acquired naevi can have unique dermoscopic patterns that correspond to distinct microanatomical growth patterns. Previous studies on acquired naevi stratified according to dermoscopic pattern focused on the frequency of somatic BRAF mutations, whereas NRAS mutations remained to be elucidated. OBJECTIVES: To investigate the BRAF and NRAS mutation prevalence and activation of the mitogen-activated protein kinase (MAPK) pathway in distinct dermoscopic subtypes of acquired naevi. METHODS: Common mutations present in BRAF and NRAS were assessed in 40 globular, reticular and peripheral rim of globules (PG) subtypes of acquired naevi from 27 participants (19 male, 8 female; mean age 46·7 years) selected from 1261 eligible volunteers. Mutations were determined using the highly sensitive and quantitative QX200 droplet digital™ polymerase chain reaction (ddPCR) system. RESULTS: The BRAF V600E (c.1799T>A or c.1799_1800delTGinsA) and BRAF V600K mutations were detected in 85% (n = 34/40) of naevi. All BRAF wild-type naevi (15%; n = 6/40) harboured an NRAS codon 12/13 or 61 mutation. BRAF mutations were present in 92% (n = 12/13) of globular and 100% (n = 12/12) of PG naevi, whereas reticular naevi were 67% (n = 10/15) BRAF- and 33% (n = 5/15) NRAS-mutant (P = 0·037). CONCLUSIONS: We discovered that 100% of the assessed acquired naevi had either a BRAF or NRAS mutation. Using sensitive techniques capable of single-cell mutation detection, it is likely that all acquired naevi will be mutated for BRAF or NRAS. Because both of these mutations are prevalent in distinct dermoscopic naevus subsets, our study supports the role of the MAPK pathway in the development of benign melanocytic proliferations, indicating that additional genomic events besides somatic mutations in BRAF or NRAS are required for melanoma development.
引用
- Tan JM, Tom LN, Jagirdar K, et al. The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation. Br J Dermatol. 2017. PMID: 28714107. doi:10.1111/bjd.15809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。